Blood Test Offers Improved Breast Cancer Detection
By LabMedica International staff writers Posted on 16 Jun 2017 |
Image: The Videssa Breast protein biomarker blood test for breast cancer evaluates 11 serum protein biomarkers and 33 tumor-associated autoantibodies (Photo courtesy of Provista Diagnostics).
Breast cancer is predicted to be the second leading cause of cancer deaths in the USA women. Approximately 232,000 cases of invasive breast cancer and 60,000 cases of ductal carcinoma in situ (DCIS) are diagnosed and 40,000 deaths occur annually.
A multi-protein biomarker blood test that is able to detect breast cancer can help inform better decision-making after abnormal mammogram or other breast imaging results and potentially reduce use of biopsy by up to 67%. If diagnosed early in a localized state, five-year survival rates are greater than 98%.
Medical scientists working with a privately held molecular diagnostics company carried out two prospective, randomized, multi-center and blinded clinical trials, in more than 1,350 patients, ages 25-75. It is the first prospective study of a proteomic assay composed of serum protein biomarkers and tumor-associated autoantibodies being used to detect breast cancer in women with abnormal imaging results. Serum was evaluated for 11 serum protein biomarkers and 33 tumor-associated autoantibodies.
The team used the Videssa Breast (Provista Diagnostics, Inc, New York, NY, USA), which is the first blood-based proteomic test of its kind to provide early and accurate detection of breast cancer. The overall performance of Videssa Breast in women with a breast cancer prevalence of 5.87% resulted in a sensitivity of 87.5%, specificity of 83.8%, positive predictive value (PPV) of 25.2% and a negative predictive value (NPV) of 99.1%.
The authors noted that that the high NPV helps clinicians identify patients who are highly unlikely to have breast cancer. Depending on age, approximately 70% to 90% of breast biopsies are benign. The improved PPV of Videssa Breast over imaging of 25.2% versus 8.8% can increase the percentage of biopsies that yield a breast cancer diagnosis from one in 11 to one in four.
Josie R. Alpers, MD, a radiologist specializing in mammography and diagnostic radiology, and co-author, said, “When a mammogram yields an abnormal result, the challenge for every clinician is to decide which patients need follow-up, further imaging or biopsy. A test that is well-validated in a prospective trial means clinicians have a new way to accurately identify which patients may or may not need additional follow-up.” The study was published on May 23, 2017, in the journal Clinical Breast Cancer.
Related Links:
Provista Diagnostics
A multi-protein biomarker blood test that is able to detect breast cancer can help inform better decision-making after abnormal mammogram or other breast imaging results and potentially reduce use of biopsy by up to 67%. If diagnosed early in a localized state, five-year survival rates are greater than 98%.
Medical scientists working with a privately held molecular diagnostics company carried out two prospective, randomized, multi-center and blinded clinical trials, in more than 1,350 patients, ages 25-75. It is the first prospective study of a proteomic assay composed of serum protein biomarkers and tumor-associated autoantibodies being used to detect breast cancer in women with abnormal imaging results. Serum was evaluated for 11 serum protein biomarkers and 33 tumor-associated autoantibodies.
The team used the Videssa Breast (Provista Diagnostics, Inc, New York, NY, USA), which is the first blood-based proteomic test of its kind to provide early and accurate detection of breast cancer. The overall performance of Videssa Breast in women with a breast cancer prevalence of 5.87% resulted in a sensitivity of 87.5%, specificity of 83.8%, positive predictive value (PPV) of 25.2% and a negative predictive value (NPV) of 99.1%.
The authors noted that that the high NPV helps clinicians identify patients who are highly unlikely to have breast cancer. Depending on age, approximately 70% to 90% of breast biopsies are benign. The improved PPV of Videssa Breast over imaging of 25.2% versus 8.8% can increase the percentage of biopsies that yield a breast cancer diagnosis from one in 11 to one in four.
Josie R. Alpers, MD, a radiologist specializing in mammography and diagnostic radiology, and co-author, said, “When a mammogram yields an abnormal result, the challenge for every clinician is to decide which patients need follow-up, further imaging or biopsy. A test that is well-validated in a prospective trial means clinicians have a new way to accurately identify which patients may or may not need additional follow-up.” The study was published on May 23, 2017, in the journal Clinical Breast Cancer.
Related Links:
Provista Diagnostics
Latest Pathology News
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities